[HTML][HTML] Comparing the efficacy of anti-seizure medications using matched cohorts on a large insurance claims database
Epilepsy is a severe chronic neurological disease affecting 60 million people worldwide.
Primary treatment is with anti-seizure medicines (ASMs), but many patients continue to …
Primary treatment is with anti-seizure medicines (ASMs), but many patients continue to …
Comparing the efficacy of anti-seizure medications using matched cohorts on a large insurance claims database
L Ness, L Szlak, F Benninger, S Ravid… - Epilepsy …, 2024 - research.ibm.com
Epilepsy is a severe chronic neurological disease affecting 60 million people worldwide.
Primary treatment is with anti-seizure medicines (ASMs), but many patients continue to …
Primary treatment is with anti-seizure medicines (ASMs), but many patients continue to …
Comparing the efficacy of anti-seizure medications using matched cohorts on a large insurance claims database.
Y Kan-Tor, L Ness, L Szlak, F Benninger… - Epilepsy …, 2024 - europepmc.org
Epilepsy is a severe chronic neurological disease affecting 60 million people worldwide.
Primary treatment is with anti-seizure medicines (ASMs), but many patients continue to …
Primary treatment is with anti-seizure medicines (ASMs), but many patients continue to …
Comparing the efficacy of anti-seizure medications using matched cohorts on a large insurance claims database
Y Kan-Tor, L Ness, L Szlak, F Benninger… - Epilepsy … - pubmed.ncbi.nlm.nih.gov
Epilepsy is a severe chronic neurological disease affecting 60 million people worldwide.
Primary treatment is with anti-seizure medicines (ASMs), but many patients continue to …
Primary treatment is with anti-seizure medicines (ASMs), but many patients continue to …